Dexamethasone Treatment Options in United Kingdom (Updated 8/25)

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

NCT00057564

Completed

To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/09/2015

Locations: Clinical Research Consultants, Inc., Hoover, Alabama +98 locations

Clinical Research Consultants, Inc., Hoover, Alabama

Arizona Clinical Research Center, Tucson, Arizona

UCLA School of Medicine, Los Angeles, California

James Berenson, West Hollywood, California

Mayo Clinic, Jacksonville, Florida

Melbourne Internal Medicine Associates Oncology, Melbourne, Florida

Jackson Memorial Hospital and Clinics, Miami, Florida

University of Miami Miller School/Jackson Memorial Hospital, Miami, Florida

University of Miami, Miami, Florida

Oncology Hematology Group of South Florida, Miami, Florida

Medical College of Georgia, Augusta, Georgia

Southern Illinois Hematology /Oncology, Centralia, Illinois

Rush Cancer Institute Section of Hematology, Chicago, Illinois

University of Iowa Hospital of Clinic, Iowa City, Iowa

Ocshner Clinic Foundation, New Orleans, Louisiana

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Mayo Clinic Cancer Center, Rochester, Minnesota

Hackensack University Hospital, Hackensack, New Jersey

SUNY Upstate Medical University, Syracuse, New York

Wake Forest University School of Medicine, Winston-Salem, North Carolina

Cleveland Clinic- Taussig Cancer Center, Cleveland, Ohio

University of Pittsburgh, Pittsburgh, Pennsylvania

South Carolina Oncology Group, West Columbia, South Carolina

The Family Centre, PLLC, Collierville, Tennessee

East Tennessee Oncology/Hematology Associates, Knoxville, Tennessee

Medical College of Wisconsin, Milwaukee, Wisconsin

Royal Brisbane Hospital, Herston, Queensland

Haematology Princess Alexandra Hospital, Woolloongabba, Queensland

Frankston Hospital, Frankston, Victoria

Peter MacCallum Cancer Institute, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Bone Marrow Transplant Service Dept of Clinical Haematology and Medical Oncology, Parkville, Victoria

Institut Jules Bordet Dep't of Clinical Haematology, Brussels, Not set

Dept. Of Haematology Academisch Ziekenhuis VUB, Brussels, Not set

University Hospital Ghent Dep't of Haematology, Ghent, Not set

UMHAT Alexandrovska, Alexandrovska, Not set

National Center of Haematology and Transfusiology, Sofia, Not set

Military Medical Academy, Sofia, Not set

Dalhousie University, Halifax, Nova Scotia

Princess Margaret Hospital, Toronto, Ontario

University Health Network Princess Margaret Hospital, Toronto, Ontario

Centre Hopitalier Universitaire de Sherbrooke Hospital Fleurimont, Fleurimont, Quebec

McGill University, Montreal, Quebec

Saskatoon Cancer Centre University of Saskatoon, Saskatoon, Saskatchewan

Universitaetsklinikum Dusseldorf Klinik fuer Haematologie, Dusseldorf, Not set

St. Laszlo Hoszpital, Budapest, Not set

Petz Aladar County Hospital, Gyor, Not set

MidWestern Regional Hospital Haematology Dpt., Dooradoyle, Limerick

Hope Directorate Dep't. Haematology St. James's Hospital, Dublin, Not set

Hadassah University Hospital Hematology Dep't, Ein Kerem, Jerusalem

Rambam Medical Center Dep't. Of Hematology, Haifa, Not set

Tel Aviv Sourasky Medical Center Hematology Institute, Tel Aviv, Not set

Director of Hematology Division BMT and CBB The Chaim Sheba Medical Center, Tel Hashomer, Not set

Universita di Bari Dipartimento di Scienze Umana Sezione de Medicina Interna e Oncologia Medica Policlinico, Bari, Not set

Istituto di Ematologia e Oncologia Medica "L. e. A. Seragnoli", Bologna, Not set

Azienda Ospedaliera San Martino, Genova, Not set

Ospedale Niguarda Ca Granda, Milano, Not set

Policlinico San Matteo, Pavia, Not set

Università La Sapienza Dipartimento di Biotecnologie Cellulari ed Ematologia, Roma, Not set

Clinica Ematologica Policlinico Universitario, Udine, Not set

Medical Academy of Bialystok, Bialystok, Not set

Institute of Internal Diseases University of Medicine, Gdansk, Not set

Jagiellonian University Collegium Medicum Department of Hematology, Krakow, Not set

Medical University of Lodz, Lodz, Not set

Private Medical Practice Centre of Clinical Laboratory of Densitometry At 'Officers of Professors', Lublin, Not set

Medical University of Warsaw Dep't of Hematology, Oncology and Internal Diseases, Warsaw, Not set

Chelyabinsk Regional Clinical Hospital Hematology Dpt, Chelyabinsk, Not set

Ekaterinburg 1st Regional Clinical Hospital Regional Hematology Centre, Ekaterinburg, Not set

Republican Clinical Hospital #1 Hematology Dpt., Izhevsk, Not set

Burdenko Central Military Clinical Hospital Hematology Center, Moscow, Not set

Russian Academy of Medical Sciences Scientific Center of Hematology, Moscow, Not set

Nizhny Novgorod Clinical Hospital, Novgorod, Not set

Novosibirsk State Regional Clinical Hospital Hematology Centre, Novosibirsk, Not set

Samara Regional Clinical Hospital Dep't. of Hematology and Bone Marrow Transplantation, Samara, Not set

Blokhin Cancer Research Center Dpt of Myeloproliferative Disorders Chemotherapy, Shosse, Not set

Research Institute of Hematology and Blood Transfusion,Clinical Department of Hematology with Bone Marrow Transplantation Unit, St. Petersburg, Not set

St. Petersburg Pavlov State Medical University Bone Marrow Transplantation Clinic, St. Petersburg, Not set

Clinical Hospital #31 Dpt of Bone Marrow Transplantation and Chemotherapy of Patients with Myeloproliferative Disorders, St. Petersburg, Not set

Hospital Clinic, Barcelona, Not set

Hospital Universitario de la Princessa, Madrid, Not set

Hospital Doce de Octubre, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Marques de Valdecilla, Santander, Not set

Universitatsspital Zurich, Zurich, Not set

Cherkassy Regional Oncology Center, Cherkassy, Not set

Dnepropetrovsk City Clinical Hospital #4 Regional Hematology Centre, Dnepropetrovsk, Not set

Ivano-Frankovsk Regional Clinical Hospital - Hospital Therapy Department, Ivano-Frankovsk, Not set

Kharkov Regional Clinical Oncology Center Dep't of Oncology and Pediatric Oncology, Kharkov, Not set

Kiev Institute of Oncology of the UAMS Systemic Malignancies Department, Kiev, Not set

Kiev Bone Marrow Transplantation Center Bone Marrow Transplantation Department, Kiev, Not set

Institute of Hematology and Transfusiology of the UAMS Department of Blood Diseases with Clinical Biochemistry Group, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of the UAMS, Lvov, Not set

Odessa Regional Clinical Hospital Hematology Dep't, Odessa, Not set

Zaporozhje Regional Clinical Hospital Hematology Dpt, Zaporozhye, Not set

Zhitomir Regional Clinical Hospital Hematology Centre, Zhitomir, Not set

Belfast City Hospital Haematology Dpt., Belfast, Not set

Guys Hospital, London, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma

NCT00915408

Completed

The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination with Lenalidomide (Revlimid®) plus dexamethasone in patients who present with relapsed or refractory myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/01/2015

Locations: King's College Hospital NHS Foundation Trust, London, Not set +1 locations

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

NCT00131261

Completed

The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2015

Locations: James Berenson, MD, Inc, West Hollywood, California +9 locations

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

NCT02145715

Unknown

Velcade (bortezomib), thalidomide and dexamethasone (VTD) has been demonstrated to be a highly effective combination in both patients with previously untreated and those with relapsed multiple myeloma. In previously untreated patients VTD demonstrated clear superiority to TD as induction therapy prior to planned tandem autologous stem cell transplant. The rationale of this trial is to combine a 'gold standard' antiMM combination with the HDAC inhibitor Panobinostat. There is emerging data to su... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/25/2015

Locations: Birmingham Heartlands Hospital, Birmingham, UK +4 locations

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403

Completed

This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety ass... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/15/2015

Locations: GSK Investigational Site, Birmingham, Alabama +112 locations

GSK Investigational Site, Birmingham, Alabama

GSK Investigational Site, Corona, California

GSK Investigational Site, Greenbrae, California

GSK Investigational Site, Loma Linda, California

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, Palm Springs, California

GSK Investigational Site, Lakewood, Colorado

GSK Investigational Site, Boynton Beach, Florida

GSK Investigational Site, Hudson, Florida

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Ocala, Florida

GSK Investigational Site, Centralia, Illinois

GSK Investigational Site, Park Ridge, Illinois

GSK Investigational Site, Skokie, Illinois

GSK Investigational Site, Evansville, Indiana

GSK Investigational Site, Muncie, Indiana

GSK Investigational Site, New Albany, Indiana

GSK Investigational Site, Hutchinson, Kansas

GSK Investigational Site, Alexandria, Louisiana

GSK Investigational Site, Baton Rouge, Louisiana

GSK Investigational Site, Bethesda, Maryland

GSK Investigational Site, Worcester, Massachusetts

GSK Investigational Site, Bay City, Michigan

GSK Investigational Site, Tupelo, Mississippi

GSK Investigational Site, Jefferson City, Missouri

GSK Investigational Site, Rolla, Missouri

GSK Investigational Site, St. Louis, Missouri

GSK Investigational Site, Sparta, New Jersey

GSK Investigational Site, Bronx, New York

GSK Investigational Site, Rochester, New York

GSK Investigational Site, Bismarck, North Dakota

GSK Investigational Site, Akron, Ohio

GSK Investigational Site, Canton, Ohio

GSK Investigational Site, Sumter, South Carolina

GSK Investigational Site, Corpus Christi, Texas

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, Houston, Texas

GSK Investigational Site, Tyler, Texas

GSK Investigational Site, Ogden, Utah

GSK Investigational Site, West Point, Utah

GSK Investigational Site, Burlington, Vermont

GSK Investigational Site, Abingdon, Virginia

GSK Investigational Site, Richmond, Virginia

GSK Investigational Site, Everett, Washington

GSK Investigational Site, Tacoma, Washington

GSK Investigational Site, Rhinelander, Wisconsin

GSK Investigational Site, Capital Federal, Buenos Aires

GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Not set

GSK Investigational Site, Salzburg, Not set

GSK Investigational Site, Vienna, Not set

GSK Investigational Site, Kitchener, Ontario

GSK Investigational Site, Oshawa, Ontario

GSK Investigational Site, Charlottetown, Prince Edward Island

GSK Investigational Site, Greenfield Park, Quebec

GSK Investigational Site, Québec, Quebec

GSK Investigational Site, Santiago, Región Metro De Santiago

GSK Investigational Site, Osijek, Not set

GSK Investigational Site, Hradec Kralove, Not set

GSK Investigational Site, Ostrava - Poruba, Not set

GSK Investigational Site, Praha 10, Not set

GSK Investigational Site, Praha 5, Not set

GSK Investigational Site, Praha 8, Not set

GSK Investigational Site, Muenchen, Bayern

GSK Investigational Site, Regensburg, Bayern

GSK Investigational Site, Essen, Nordrhein-Westfalen

GSK Investigational Site, Athens, Not set

GSK Investigational Site, Haidari, Not set

GSK Investigational Site, Thessaloniki, Not set

GSK Investigational Site, Pokfulam, Not set

GSK Investigational Site, Budapest, Not set

GSK Investigational Site, Mátraháza, Not set

GSK Investigational Site, Dublin, Not set

GSK Investigational Site, Tallaght, Dublin, Not set

GSK Investigational Site, Tullamore, Not set

GSK Investigational Site, Merida, Yucatán

GSK Investigational Site, Durango, Not set

GSK Investigational Site, Karachi, Not set

GSK Investigational Site, Lahore, Not set

GSK Investigational Site, Quezon City, Not set

GSK Investigational Site, Taft Avenue, Manila, Not set

GSK Investigational Site, Kielce, Not set

GSK Investigational Site, Olsztyn, Not set

GSK Investigational Site, Opole, Not set

GSK Investigational Site, Szczecin, Not set

GSK Investigational Site, Lisboa, Not set

GSK Investigational Site, Moscow Region, Not set

GSK Investigational Site, Moscow, Not set

GSK Investigational Site, Singapore, Not set

GSK Investigational Site, Bratislava, Not set

GSK Investigational Site, Zilina, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Marid, Not set

GSK Investigational Site, Pontevedra, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Tainan, Not set

GSK Investigational Site, Taipei, Not set

GSK Investigational Site, Bangkok, Not set

GSK Investigational Site, Chiang Mai, Not set

GSK Investigational Site, Exeter, Devon

GSK Investigational Site, Chelmsford, Essex

GSK Investigational Site, Cardiff, Glamorgan

GSK Investigational Site, Edinburgh, Midlothian

GSK Investigational Site, Shrewsbury, Not set

Conditions: Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting

Register for Updates

Learn More ›

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

NCT00908232

Completed

The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/14/2015

Locations: Not set, Bordeaux, Not set +42 locations

Not set, Bordeaux, Not set

Not set, Le Mans Cedex 2, Not set

Not set, Lille Cedex, Not set

Not set, Tours Cedex 9, Not set

Not set, Duisburg, Not set

Not set, Essen, Not set

Not set, Frankfurt An Der Oder, Not set

Not set, Leipzig, Not set

Not set, München, Not set

Not set, Mÿnchen, Not set

Not set, Oldenburg, Not set

Not set, Ulm, Not set

Not set, Athens, Not set

Not set, Patra, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Miskolc, Not set

Not set, Nyiregyhaza, Not set

Not set, Szeged, Not set

Not set, Kaunas, Not set

Not set, Klaipeda, Not set

Not set, Vilnius Lt, Not set

Not set, Bialystok, Not set

Not set, Katowice, Not set

Not set, Kraków, Not set

Not set, Lodz, Not set

Not set, Warszawa, Not set

Not set, Wroclaw, Not set

Not set, Belgrade, Not set

Not set, Nis, Not set

Not set, Novi Sad, Not set

Not set, Sremska Kamenica, Not set

Not set, Barcelona, Not set

Not set, Madrid, Not set

Not set, Toledo, Not set

Not set, Valencia, Not set

Not set, Ankara, Not set

Not set, Istambul, Not set

Not set, Istanbul, Not set

Not set, Izmir, Not set

Not set, Bath, Not set

Not set, Edinburgh, Not set

Not set, London, Not set

Conditions: Multiple Myeloma

Register for Updates

Learn More ›

PAD. ICORG 05-01, V11

NCT00814541

Completed

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with bortezomib may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with doxorubi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/30/2014

Locations: Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Not set +8 locations

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Register for Updates

Learn More ›

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01396057

Completed

This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/04/2014

Locations: Novartis Investigative Site, Praha 10, Not set +65 locations

Novartis Investigative Site, Praha 10, Not set

Novartis Investigative Site, Augsburg, Not set

Novartis Investigative Site, Bad Rothenfelde, Not set

Novartis Investigative Site, Berlin, Not set

Novartis Investigative Site, Bochum, Not set

Novartis Investigative Site, Bonn, Not set

Novartis Investigative Site, Bremen, Not set

Novartis Investigative Site, Chemnitz, Not set

Novartis Investigative Site, Darmstadt, Not set

Novartis Investigative Site, Dresden, Not set

Novartis Investigative Site, Duesseldorf, Not set

Novartis Investigative Site, Düsseldorf, Not set

Novartis Investigative Site, Frankfurt, Not set

Novartis Investigative Site, Freiburg i. Br, Not set

Novartis Investigative Site, Glauchau, Not set

Novartis Investigative Site, Göttingen, Not set

Novartis Investigative Site, Hagen, Not set

Novartis Investigative Site, Halle, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Homburg, Not set

Novartis Investigative Site, Ingolstadt, Not set

Novartis Investigative Site, Karlsruhe, Not set

Novartis Investigative Site, Kiel, Not set

Novartis Investigative Site, Koeln, Not set

Novartis Investigative Site, Leipzig, Not set

Novartis Investigative Site, Ludwigshafen, Not set

Novartis Investigative Site, Marburg, Not set

Novartis Investigative Site, Minden, Not set

Novartis Investigative Site, Muelheim, Not set

Novartis Investigative Site, Muenster, Not set

Novartis Investigative Site, Munich, Not set

Novartis Investigative Site, München, Not set

Novartis Investigative Site, Recklinghausen, Not set

Novartis Investigative Site, Regensburg, Not set

Novartis Investigative Site, Sulzbach, Not set

Novartis Investigative Site, Tübingen, Not set

Novartis Investigative Site, Ulm, Not set

Novartis Investigative Site, Wolfsburg, Not set

Novartis Investigative Site, Würzburg, Not set

Novartis Investigative Site, Budapest, Not set

Novartis Investigative Site, Debrecen, Not set

Novartis Investigative Site, Szeged, Not set

Novartis Investigative Site, Bydgoszcz, Not set

Novartis Investigative Site, Bytom, Not set

Novartis Investigative Site, Birmingham, Not set

Novartis Investigative Site, Bradford, Not set

Novartis Investigative Site, Cheshire, Not set

Novartis Investigative Site, Colchester, Not set

Novartis Investigative Site, Derby, Not set

Novartis Investigative Site, Gloucester, Not set

Novartis Investigative Site, Guildford, Surrey, Not set

Novartis Investigative Site, Kent, Not set

Novartis Investigative Site, Leeds, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Manchester, Not set

Novartis Investigative Site, Middlesborough, Not set

Novartis Investigative Site, Nottingham, Not set

Novartis Investigative Site, Portsmouth, Not set

Novartis Investigative Site, Rugby, Not set

Novartis Investigative Site, Westcliff-on-Sea, Not set

Novartis Investigative Site, York, Not set

Conditions: Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion

Register for Updates

Learn More ›

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

NCT00168337

Completed

This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/10/2014

Locations: Not set, Artesia, California +13 locations

Conditions: Diabetic Macular Edema

Register for Updates

Learn More ›

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

NCT00113607

Completed

The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/18/2014

Locations: Not set, Mobile, Alabama +112 locations

Not set, Mobile, Alabama

Not set, Tucson, Arizona

Not set, Los Angeles, California

Not set, Newport Beach, California

Not set, Orange, California

Not set, Englewood, Colorado

Not set, Stamford, Connecticut

Not set, Tampa, Florida

Not set, Coeur D Alene, Idaho

Not set, Louisville, Kentucky

Not set, New Orleans, Louisiana

Not set, Boston, Massachusetts

Not set, Minneapolis, Minnesota

Not set, Saint Louis, Missouri

Not set, Morristown, New Jersey

Not set, New York, New York

Not set, Charlotte, North Carolina

Not set, Greenville, North Carolina

Not set, Winston Salem, North Carolina

Not set, Cleveland, Ohio

Not set, Toledo, Ohio

Not set, Portland, Oregon

Not set, Pittsburgh, Pennsylvania

Not set, Greenville, South Carolina

Not set, Chattanooga, Tennessee

Not set, Nashville, Tennessee

Not set, Dallas, Texas

Not set, Galveston, Texas

Not set, Buenos Aires, Not set

Not set, Mendoza, Not set

Not set, Sante Fe, Not set

Not set, Adelaide, Not set

Not set, Bentleigh, Not set

Not set, Douglas, Not set

Not set, St Leonards, Not set

Not set, Toorak Gardens, Not set

Not set, Edegem, Not set

Not set, Hasselt, Not set

Not set, Leuven, Not set

Not set, Wilrijk, Not set

Not set, Barretos, Not set

Not set, Belo Horizonte, Not set

Not set, Cerqueira Cesar, Not set

Not set, Londrina, Not set

Not set, Santo Andre, Not set

Not set, Sao Paulo, Not set

Not set, Calgary, Alberta

Not set, Edmonton, Alberta

Not set, Ottawa, Ontario

Not set, Montreal, Quebec

Not set, Quebec City, Quebec

Not set, Reneca, Not set

Not set, Santiago, Not set

Not set, Beijing, Not set

Not set, Guangzhou, Not set

Not set, Hangzhou, Not set

Not set, Jinan, Not set

Not set, Shanghai, Not set

Not set, Chartres, Not set

Not set, Paris, Not set

Not set, Pierre Benite Cedex, Not set

Not set, Düsseldorf, Not set

Not set, Heidelberg, Not set

Not set, Jena, Not set

Not set, Karlsruhe, Not set

Not set, Mainz, Not set

Not set, Villingen-Schwenningen, Not set

Not set, Wilhelmshaven, Not set

Not set, Chai Wan, Not set

Not set, Hong Kong, Not set

Not set, Sha Tin, Not set

Not set, Seoul, Not set

Not set, Amsterdam, Not set

Not set, Enschede, Not set

Not set, Groningen, Not set

Not set, Maastricht, Not set

Not set, Gdansku, Not set

Not set, Gliwice, Not set

Not set, Krakow, Not set

Not set, Olsztyn, Not set

Not set, Poznan, Not set

Not set, Warszawa Poland, Not set

Not set, Wroclaw, Not set

Not set, Chelyabinsk, Not set

Not set, Moscow N/A, Not set

Not set, Moscow, Not set

Not set, Obninsk, Kaluga Region, Not set

Not set, Orenburg, Not set

Not set, Saint Petersburg, Not set

Not set, Samara, Not set

Not set, St. Petersburg, Not set

Not set, Singapore, Not set

Not set, Barcelona, Not set

Not set, Girona, Not set

Not set, Guadalajara, Not set

Not set, L'Hospitalet De Llobregat, Not set

Not set, Madrid, Not set

Not set, Maranon, Not set

Not set, Valencia, Not set

Not set, Zaragoza, Not set

Not set, Göteborg, Not set

Not set, Umeå, Not set

Not set, Uppsala, Not set

Not set, Kaohsiung County, Not set

Not set, Taipei, Not set

Not set, Tao-Yuan, Not set

Not set, Birmingham, Not set

Not set, Edinburgh, Not set

Not set, Leicester, Not set

Not set, London, Not set

Not set, Nottingham, Not set

Not set, Poole, Not set

Not set, Sheffield, Not set

Conditions: Ovarian Cancer

Register for Updates

Learn More ›

A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy

NCT00473512

Completed

The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose \[MTD\]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).

Gender:

MALE

Ages:

18 years and above

Trial Updated:

02/27/2014

Locations: Not set, Sutton, Not set

Conditions: Prostatic Neoplasms

Register for Updates

Learn More ›

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

NCT00003423

Unknown

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating children who have newly diagnosed non-Hodgkin's lymphoma.

Gender:

ALL

Ages:

14 years and below

Trial Updated:

12/18/2013

Locations: Hospital for Sick Children NHS Trust, London, England

Conditions: Lymphoma

Register for Updates

Learn More ›

Dexamethasone Treatment Options in United Kingdom

Match to Clinical Trials